Beta Bionics opened lower at $17.67, compared with its previous close of $17.81. In the last trading session, the stock traded between $16.66 and $17.67. It showed a downward intraday trend.
An investment of $100 made 2 years ago in Beta Bionics is now worth
$ 69.59
Resulting in a loss of
$ 30.41 (30.41%)
Note: Past profits do not guarantee future returns.
Rating from 13 Analysts
Today's Change
$-1.37 (-7.67%)
Day High
$17.67
Day Low
$16.66
Day Open
$17.67
Prev Close
$17.81
Volume
7,34,755
1W Return
-2.87%
1M Return
-7.92%
3M Return
-6.49%
6M Return
66.94%
1Y Return
-42.94%
Market Cap ($ Mn)
894
PE Ratio
-
PB Ratio
3.46
PEG Ratio
-
ROE
-38.43%
ROCE
-30.86%
EPS (TTM)
-
1 Week
-2.87%
1 Month
-7.92%
3 Months
-6.49%
6 Months
66.94%
9 Months
16.46%
Beta Bionics investors face November 3 lead plaintiff deadline
Lead plaintiff deadline for Beta Bionics securities class action is November 3, 2026. Class period covers securities purchased between July 30, 2025 and February 24, 2026. Complaint alleges misleading statements about FDA Form 483 findings and iLet pump safety. Faruqi & Faruqi LLP urges affected investors to contact them to discuss legal rights.
10 days agoRosen Law Firm urges Beta Bionics investors to meet Nov 3 deadline
Rosen Law Firm urges Beta Bionics investors to file lead plaintiff applications by November 3, 2026. Class period covers stock purchases between July 30, 2025, and February 24, 2026. Complaint alleges management misled investors about iLet insulin pump safety and FDA compliance. Stock price declined approximately 72% from pre-disclosure peak following safety revelations.
22 days agoRosen Law urges Beta Bionics investors to act before Nov 3 deadline
Rosen Law Firm reminds Beta Bionics investors of the November 3, 2026, lead plaintiff deadline. Class action alleges concealment of FDA warnings regarding iLet device safety risks. Stock price fell approximately 72% from Class Period high following disclosure of issues.
1mo agoBeta Bionics signs deal to integrate iLet with Senseonics’ Eversense 365
Beta Bionics integrates iLet and mint systems with Senseonics’ Eversense 365 CGM. Commercial launch of integrated iLet and Eversense 365 expected in Q4 2026. Integration aims to maximize CGM manufacturer options for automated insulin delivery users. Future commitment announced for integrating mint platform with Eversense 365.
1mo agoBeta Bionics closes $172.5 million stock offering after full option exercise
Beta Bionics closed a $172.5 million public offering on September 17, 2026. Underwriters exercised their full option to buy 1,304,348 additional shares. Initial pricing was set at $17.25 per share on September 15, 2026. Proceeds will fund Mint commercialization, R&D, and working capital. Shares fell 7.1% in pre-market trading ahead of the closing announcement.
1mo agoBeta Bionics cuts FY26 sales guide to $121M-$126M on Mint delay
Beta Bionics cut FY26 revenue guidance to $121M-$126M from $131M-$136M due to $10M in deferred sales. FDA cleared Mint pump, but full US commercial launch delayed to Q1 2027. Company expects to recapture lost Q4FY26 revenue through Mint sales in FY27. Gross margin guidance for FY26 remains unchanged at 58.5%-59.5%. New 3D Intelligence algorithm submitted to FDA for next-gen devices.
1mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $109.29 | -1.06% | $1,89,283.94M | 36.28 | |
| $449.53 | -0.11% | $1,55,826.88M | 42.73 | |
| $101.61 | +0.02% | $1,29,976.46M | 24.46 | |
| $318.79 | -1.70% | $1,21,360.48M | 34.27 | |
| $45.13 | +0.96% | $65,414.72M | 18.96 | |
| $105.81 | +1.73% | $60,840.75M | 53.70 | |
| $214.52 | +0.90% | $58,432.46M | 44.07 | |
| $82.60 | -1.26% | $37,346.60M | 16.49 | |
| $42.16 | +3.06% | $37,044.18M | 89.05 | |
| $72.46 | -2.16% | $35,027.16M | 54.55 | |
| $237.20 | +1.61% | $33,458.08M | 23.04 | |
| $80.35 | +0.53% | $29,964.75M | 36.04 |
An investment of $100 made 2 years ago in Beta Bionics is now worth
$ 69.59
Resulting in a loss of
$ 30.41 (30.41%)
Note: Past profits do not guarantee future returns.
